These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34783191)

  • 1. Predicting Liver-Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests.
    Johnson AL; Hayward KL; Patel P; Horsfall LU; Cheah AEZ; Irvine KM; Russell AW; Stuart KA; Williams S; Hartel G; Valery PC; Powell EE
    Hepatol Commun; 2022 Apr; 6(4):728-739. PubMed ID: 34783191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
    Pennisi G; Enea M; Falco V; Aithal GP; Palaniyappan N; Yilmaz Y; Boursier J; Cassinotto C; de Lédinghen V; Chan WK; Mahadeva S; Eddowes P; Newsome P; Karlas T; Wiegand J; Wong VW; Schattenberg JM; Labenz C; Kim W; Lee MS; Lupsor-Platon M; Cobbold JFL; Fan JG; Shen F; Staufer K; Trauner M; Stauber R; Nakajima A; Yoneda M; Bugianesi E; Younes R; Gaia S; Zheng MH; Cammà C; Anstee QM; Mózes FE; Pavlides M; Petta S
    Hepatology; 2023 Jul; 78(1):195-211. PubMed ID: 36924031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care.
    Patel P; Hossain F; Horsfall LU; Banh X; Hayward KL; Williams S; Johnson T; Bernard A; Brown NN; Lampe G; Buck L; Saad N; Russell AW; Valery PC; Irvine KM; Clouston AD; Stuart KA; Rosenberg W; Powell EE
    Hepatol Commun; 2018 Aug; 2(8):893-905. PubMed ID: 30094401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
    Kjaergaard M; Lindvig KP; Thorhauge KH; Andersen P; Hansen JK; Kastrup N; Jensen JM; Hansen CD; Johansen S; Israelsen M; Torp N; Trelle MB; Shan S; Detlefsen S; Antonsen S; Andersen JE; Graupera I; Ginés P; Thiele M; Krag A
    J Hepatol; 2023 Aug; 79(2):277-286. PubMed ID: 37088311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis.
    Chan WK; Treeprasertsuk S; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Dan YY; Imajo K; Nakajima A; Ho KY; Goh KL; Wong VW
    Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2570-2580.e37. PubMed ID: 30876959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
    Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
    Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease.
    Petta S; Sebastiani G; Viganò M; Ampuero J; Wai-Sun Wong V; Boursier J; Berzigotti A; Bugianesi E; Fracanzani AL; Cammà C; Enea M; Grottes MD; Di Marco V; Younes R; Keyrouz A; Mazzola S; Mendoza Y; Pennisi G; Romero-Gomez M; Craxì A; de Ledinghen V
    Clin Gastroenterol Hepatol; 2021 Apr; 19(4):806-815.e5. PubMed ID: 32621970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Wai-Sun Wong V; Bugianesi E; Fracanzani AL; Cammà C; Hiriart JB; Lai-Hung Wong G; Vergniol J; Wing-Hung Chan A; Giannetti A; Merrouche W; Lik-Yuen Chan H; Le-Bail B; Lombardi R; Guastella S; Craxì A; de Ledinghen V
    Am J Gastroenterol; 2019 Jun; 114(6):916-928. PubMed ID: 31169533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis.
    Mózes FE; Lee JA; Vali Y; Alzoubi O; Staufer K; Trauner M; Paternostro R; Stauber RE; Holleboom AG; van Dijk AM; Mak AL; Boursier J; de Saint Loup M; Shima T; Bugianesi E; Gaia S; Armandi A; Shalimar ; Lupșor-Platon M; Wong VW; Li G; Wong GL; Cobbold J; Karlas T; Wiegand J; Sebastiani G; Tsochatzis E; Liguori A; Yoneda M; Nakajima A; Hagström H; Akbari C; Hirooka M; Chan WK; Mahadeva S; Rajaram R; Zheng MH; George J; Eslam M; Petta S; Pennisi G; Viganò M; Ridolfo S; Aithal GP; Palaniyappan N; Lee DH; Ekstedt M; Nasr P; Cassinotto C; de Lédinghen V; Berzigotti A; Mendoza YP; Noureddin M; Truong E; Fournier-Poizat C; Geier A; Martic M; Tuthill T; Anstee QM; Harrison SA; Bossuyt PM; Pavlides M;
    Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):704-713. PubMed ID: 37290471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population.
    Graupera I; Thiele M; Serra-Burriel M; Caballeria L; Roulot D; Wong GL; Fabrellas N; Guha IN; Arslanow A; Expósito C; Hernández R; Aithal GP; Galle PR; Pera G; Wong VW; Lammert F; Ginès P; Castera L; Krag A;
    Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2567-2576.e6. PubMed ID: 34971806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of the Enhanced Liver Fibrosis Test in Patients With Type 2 Diabetes Mellitus and Its Clinical Implications.
    Arai T; Takahashi H; Seko Y; Toyoda H; Hayashi H; Yamaguchi K; Iwaki M; Yoneda M; Shima T; Fujii H; Morishita A; Kawata K; Tomita K; Kawanaka M; Yoshida Y; Ikegami T; Notsumata K; Oeda S; Atsukawa M; Kamada Y; Sumida Y; Fukushima H; Miyoshi E; Aishima S; Okanoue T; Itoh Y; Nakajima A;
    Clin Gastroenterol Hepatol; 2024 Apr; 22(4):789-797.e8. PubMed ID: 38048934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.
    Treeprasertsuk S; Björnsson E; Enders F; Suwanwalaikorn S; Lindor KD
    World J Gastroenterol; 2013 Feb; 19(8):1219-29. PubMed ID: 23482703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically Significant Fibrosis Is Associated With Longitudinal Increases in Fibrosis-4 and Nonalcoholic Fatty Liver Disease Fibrosis Scores.
    Patel PJ; Cheng JC; Banh X; Gracen L; Radford-Smith D; Hossain F; Horsfall LU; Hayward KL; Williams S; Johnson T; Brown NN; Saad N; Stuart KA; Russell AW; Valery PC; Clouston AD; Irvine KM; Bernard A; Powell EE
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):710-718.e4. PubMed ID: 31352092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.
    Petta S; Vanni E; Bugianesi E; Di Marco V; Cammà C; Cabibi D; Mezzabotta L; Craxì A
    Liver Int; 2015 May; 35(5):1566-73. PubMed ID: 24798049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis.
    Chan WK; Nik Mustapha NR; Mahadeva S
    Hepatol Int; 2015 Oct; 9(4):594-602. PubMed ID: 25788185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Fibrosis-4, liver-stiffness measurement, and Fibroscan-AST score to predict liver-related outcomes in nonalcoholic fatty liver disease.
    Wong YJ; Urias E; Song MW; Goyal T; Tay WX; Han NX; Loo JH; Qiu TY; Wijarnpreecha K; Chan YH; Chen VL
    Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37738409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study.
    Julián MT; Pera G; Soldevila B; Caballería L; Julve J; Puig-Jové C; Morillas R; Torán P; Expósito C; Puig-Domingo M; Castelblanco E; Franch-Nadal J; Cusi K; Mauricio D; Alonso N
    Eur J Endocrinol; 2021 Apr; 184(4):587-596. PubMed ID: 33606661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
    Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.